MHRA (United Kingdom) approves Brukinsa for the treatment of adultswith Waldenström’s macroglobulinemia.
Although the primary endpoint of statistical superiority related to deep response, very good partial response (VGPR) or better, was not met in the Phase III ASPEN trial, Brukinsa demonstrated a higher VGPR rate – 28% (29/102) compared to 19% in ibrutinib (19/99). In addition, 94% of patients on Brukinsa (n=102) continued to respond for a year or longer compared with 88% of patients on ibrutinib (n=99) who continued to respond for a year or longer. Additionally, compared to ibrutinib, Brukinsa demonstrated a lower frequency of certain adverse events, including atrial fibrillation or flutter (2/101, 2.0% vs. 15/98, 15.3%), minor bleeding (49/101, 48.5% vs. 58/98, 59.2%), and major haemorrhage (6/101, 5.9% vs. 9/98, 9.2%).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins